Thrombotic complications associated with stem cell transplantation

Blood Reviews

Volumn 26, Issue 5, 2012, Pages 183-187

  Nadir, Yona ^a   Brenner, Benjamin ^b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

DAH; Endothelial cells; SCT; Thrombosis; TMA; VOD

Indexed keywords

CYCLOSPORIN A; DEFIBROTIDE; ENDOTHELIN; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CAUSAL ATTRIBUTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER VEIN OBSTRUCTION; LIVER VENOOCCLUSIVE DISEASE; LUNG HEMORRHAGE; NONHUMAN; PATHOGENESIS; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ANIMALS; HUMANS; STEM CELL TRANSPLANTATION; THROMBOSIS;

EID: 84865178135     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2012.05.001     Document Type: Article

References (100)

1. Nadir Y., Hoffman R., Brenner B. Drug-related thrombosis in hematologic malignancies. Rev Clin Exp Hematol 2004, 8:E4.
2. Piguet P.F., Grau G.E., Collart M.A., Vassalli P., Kapanci Y. Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis. Lab Invest 1989, 61:37-45.
3. McDonald G.B., Sharma P., Matthews D.E., Shulman H.M., Thomas E.D. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984, 4:116-122.
4. Bearman S.I. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995, 85:3005-3020.
5. Richardson P., Guinan E. The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol 1999, 107:485-493.
6. Richardson P., Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol 2001, 106:57-68.
7. Carreras E., Bertz H., Arcese W., Vernant J.P., Tomas J.F., Hagglund H., et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998, 92:3599-3604.
8. McDonald G.B., Hinds M.S., Fisher L.D., Schoch H.G., Wolford J.L., Banaji M., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993, 118:255-267.
9. Braet F., Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 2002, 1:1.
10. DeLeve L.D., Ito Y., Bethea N.W., McCuskey M.K., Wang X., McCuskey R.S. Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome. Am J Physiol Gastrointest Liver Physiol 2003, 284:G1045-G1052.
11. Bearman S.I., Anderson G.L., Mori M., Hinds M.S., Shulman H.M., McDonald G.B. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993, 11:1729-1736.
12. DeLeve L.D., Shulman H.M., McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002, 22:27-42.
13. Shulman H.M., Gown A.M., Nugent D.J. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987, 127:549-558.
14. Shulman H.M., Fisher L.B., Schoch H.G., Henne K.W., McDonald G.B. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994, 19:1171-1181.
15. DeLeve L.D. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996, 24:830-837.
16. Hassan M., Ljungman P., Ringden O., Hassan Z., Oberg G., Nilsson C., et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000, 25:915-924.
17. de Jonge M.E., Huitema A.D., Beijnen J.H., Rodenhuis S. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 2006, 94:1226-1230.
18. el Mouelhi M., Kauffman F.C. Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver. Hepatology 1986, 6:450-456.
19. Deleve L.D. Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 1994, 268:1261-1270.
20. Teicher B.A., Crawford J.M., Holden S.A., Lin Y., Cathcart K.N., Luchette C.A., et al. Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide. Cancer 1988, 62:1275-1281.
21. Salat C., Holler E., Reinhardt B., Kolb H.J., Seeber B., Ledderose G., et al. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant 1994, 14:747-750.
22. Nurnberger W., Michelmann I., Burdach S., Gobel U. Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998, 76:61-65.
23. Pihusch V., Pihusch M., Penovici M., Kolb H.J., Hiller E., Pihusch R. Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation. Thromb Res 2005, 116:233-240.
24. Anscher M.S., Peters W.P., Reisenbichler H., Petros W.P., Jirtle R.L. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993, 328:1592-1598.
25. Scrobohaci M.L., Drouet L., Monem-Mansi A., Devergie A., Baudin B., D'Agay M.F., et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res 1991, 63:509-519.
26. Ferra C., de Sanjose S., Gallardo D., Berlanga J.J., Rueda F., Marin D., et al. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Haematologica 1998, 83:1082-1087.
27. Duggan C., Schmidt M., Lawler M., White B., Cusack S., McCann S., et al. The prothrombin gene variant G20210A but not factor V leiden may be associated with veno-occlusive disease following BMT. Bone Marrow Transplant 1999, 24:693-694.
28. Ertem M., Akar N. Factor V Leiden mutation as a predisposing factor for veno-occlusive disease following BMT. Bone Marrow Transplant 2000, 25:1110-1111.
29. Pidala J., Kim J., Anasetti C., Kharfan-Dabaja M.A., Nishihori T., Field T., et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol 2010, 3:36.
30. Ohashi K., Tanabe J., Watanabe R., Tanaka T., Sakamaki H., Maruta A., et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000, 64:32-38.
31. Essell J.H., Thompson J.M., Harman G.S., Halvorson R.D., Snyder M.J., Callander N.S., et al. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1992, 10:367-372.
32. Essell J.H., Schroeder M.T., Harman G.S., Halvorson R., Lew V., Callander N., et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128:975-981.
33. Ruutu T., Eriksson B., Remes K., Juvonen E., Volin L., Remberger M., et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002, 100:1977-1983.
34. Attal M., Huguet F., Rubie H., Huynh A., Charlet J.P., Payen J.L., et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992, 79:2834-2840.
35. Or R., Nagler A., Shpilberg O., Elad S., Naparstek E., Kapelushnik J., et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996, 61:1067-1071.
36. Simon M., Hahn T., Ford L.A., Anderson B., Swinnich D., Baer M.R., et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 2001, 27:627-633.
37. Park S.H., Lee M.H., Lee H., Kim H.S., Kim K., Kim W.S., et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002, 29:137-143.
38. Forrest D.L., Thompson K., Dorcas V.G., Couban S.H., Pierce R. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant 2003, 31:1143-1149.
39. Richardson P., Bearman S.I. Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy. Leuk Lymphoma 1998, 31:267-277.
40. Bearman S.I., Lee J.L., Baron A.E., McDonald G.B. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997, 89:1501-1506.
41. Bajwa R.P., Cant A.J., Abinun M., Flood T.J., Hodges S., Hale J.P., et al. Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment. Bone Marrow Transplant 2003, 31:591-597.
42. Wadleigh M., Richardson P.G., Zahrieh D., Lee S.J., Cutler C., Ho V., et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003, 102:1578-1582.
43. Richardson P.G., Elias A.D., Krishnan A., Wheeler C., Nath R., Hoppensteadt D., et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998, 92:737-744.
44. Chopra R., Eaton J.D., Grassi A., Potter M., Shaw B., Salat C., et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000, 111:1122-1129.
45. Abecasis M.M., Conceicao Silva J.P., Ferreira I., Guimaraes A., Machado A. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation. Bone Marrow Transplant 1999, 23:843-846.
46. Coccheri S., Biagi G., Legnani C., Bianchini B., Grauso F. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol 1988, 35:151-156.
47. Berti F., Rossoni G., Biasi G., Buschi A., Mandelli V., Tondo C. Defibrotide, by enhancing prostacyclin generation, prevents endothelin-1 induced contraction in human saphenous veins. Prostaglandins 1990, 40:337-350.
48. Zhou Q., Chu X., Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 1994, 71:507-510.
49. Ulutin O.N. Antithrombotic effect and clinical potential of defibrotide. Semin Thromb Hemost 1993, 19(Suppl. 1):186-191.
50. Palmer K.J., Goa K.L. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993, 45:259-294.
51. Koehl G.E., Geissler E.K., Iacobelli M., Frei C., Burger V., Haffner S., et al. Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo. Cancer Biol Ther 2007, 6.
52. Falanga A., Vignoli A., Marchetti M., Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003, 17:1636-1642.
53. Richardson P.G., Murakami C., Jin Z., Warren D., Momtaz P., Hoppensteadt D., et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002, 100:4337-4343.
54. Richardson P.G., Soiffer R.J., Antin J.H., Uno H., Jin Z., Kurtzberg J., et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010, 16:1005-1017.
55. Haussmann U., Fischer J., Eber S., Scherer F., Seger R., Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 2006, 91:795-800.
56. Dignan F., Gujral D., Ethell M., Evans S., Treleaven J., Morgan G., et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 2007, 40:79-82.
57. Cappelli B., Chiesa R., Evangelio C., Biffi A., Roccia T., Frugnoli I., et al. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan. Br J Haematol 2009, 147:554-560.
58. Pihusch R., Salat C., Schmidt E., Gohring P., Pihusch M., Hiller E., et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002, 74:1303-1309.
59. Iacopino P., Pucci G., Arcese W., Bosi A., Falda M., Locatelli F., et al. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant 1999, 24:47-51.
60. Elliott M.A., Nichols W.L., Plumhoff E.A., Ansell S.M., Dispenzieri A., Gastineau D.A., et al. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc 2003, 78:421-430.
61. Batts E.D., Lazarus H.M. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?. Bone Marrow Transplant 2007, 40:709-719.
62. Daly A.S., Xenocostas A., Lipton J.H. Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant 2002, 30:709-715.
63. Kersting S., Koomans H.A., Hene R.J., Verdonck L.F. Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival. Bone Marrow Transplant 2007, 39:359-365.
64. Martinez M.T., Bucher C., Stussi G., Heim D., Buser A., Tsakiris D.A., et al. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 2005, 36:993-1000.
65. Pettitt A.R., Clark R.E. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994, 14:495-504.
66. Tezcan H., Zimmer W., Fenstermaker R., Herzig G.P., Schriber J. Severe cerebellar swelling and thrombotic thrombocytopenic purpura associated with FK506. Bone Marrow Transplant 1998, 21:105-109.
67. Cho B.S., Min C.K., Eom K.S., Kim Y.J., Kim H.J., Lee S., et al. Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:813-820.
68. Teshima T., Miyoshi T., Ono M. Cyclosporine-related encephalopathy following allogeneic bone marrow transplantation. Int J Hematol 1996, 63:161-164.
69. Zoja C., Furci L., Ghilardi F., Zilio P., Benigni A., Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest 1986, 55:455-462.
70. Fogo A., Hakim R.C., Sugiura M., Inagami T., Kon V. Severe endothelial injury in a renal transplant patient receiving cyclosporine. Transplantation 1990, 49:1190-1192.
71. Burke G.W., Ciancio G., Cirocco R., Markou M., Olson L., Contreras N., et al. Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement. Transplantation 1999, 68:1336-1342.
72. Nakamae H., Yamane T., Hasegawa T., Nakamae M., Terada Y., Hagihara K., et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 2006, 81:525-531.
73. Corti P., Uderzo C., Tagliabue A., Della Volpe A., Annaloro C., Tagliaferri E., et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant 2002, 29:542-543.
74. Alessandrino E.P., Martinelli G., Canevari A., Bernasconi P., Caldera D., Colombo A., et al. Prompt response to high-dose intravenous immunoglobulins given as first-line therapy in post-transplant thrombotic thrombocytopenic purpura. Bone Marrow Transplant 2000, 25:1217-1218.
75. Ho V.T., Weller E., Lee S.J., Alyea E.P., Antin J.H., Soiffer R.J. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001, 7:223-229.
76. Metcalf J.P., Rennard S.I., Reed E.C., Haire W.D., Sisson J.H., Walter T., et al. Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. University of Nebraska Medical Center Bone Marrow Transplant Group. Am J Med 1994, 96:327-334.
77. Baker W.J., Vukelja S.J., Burrell L.M., Lee N., Perry J.J. High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer: long-term results. Bone Marrow Transplant 1998, 21:775-778.
78. Chao N.J., Duncan S.R., Long G.D., Horning S.J., Blume K.G. Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Ann Intern Med 1991, 114:145-146.
79. Frankovich J., Donaldson S.S., Lee Y., Wong R.M., Amylon M., Verneris M.R. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant 2001, 7:49-57.
80. Majhail N.S., Parks K., Defor T.E., Weisdorf D.J. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant 2006, 12:1038-1046.
81. Majhail N.S., Parks K., Defor T.E., Weisdorf D.J. Alveolar hemorrhage following allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Bone Marrow Transplant 2006, 38:765-768.
82. Jules-Elysee K., Stover D.E., Yahalom J., White D.A., Gulati S.C. Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation. Am Rev Respir Dis 1992, 146:485-491.
83. Robbins R.A., Linder J., Stahl M.G., Thompson A.B., Haire W., Kessinger A., et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 1989, 87:511-518.
84. Sloane J.P., Depledge M.H., Powles R.L., Morgenstern G.R., Trickey B.S., Dady P.J. Histopathology of the lung after bone marrow transplantation. J Clin Pathol 1983, 36:546-554.
85. Wojno K.J., Vogelsang G.B., Beschorner W.E., Santos G.W. Pulmonary hemorrhage as a cause of death in allogeneic bone marrow recipients with severe acute graft-versus-host disease. Transplantation 1994, 57:88-92.
86. Beschorner W.E., Shinn C.A., Hess A.D., Suresch D.L., Santos G.W. Immune-related injury to endothelium associated with acute graft-versus-host disease in the rat. Transplant Proc 1989, 21:3025-3027.
87. Corso S., Vukelja S.J., Wiener D., Baker W.J. Diffuse alveolar hemorrhage following autologous bone marrow infusion. Bone Marrow Transplant 1993, 12:301-303.
88. Mulder P.O., Meinesz A.F., de Vries E.G., Mulder N.H. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 1991, 90:278-281.
89. Meng Z.H., Dyer K., Billiar T.R., Tweardy D.J. Distinct effects of systemic infusion of G-CSF vs. IL-6 on lung and liver inflammation and injury in hemorrhagic shock. Shock 2000, 14:41-48.
90. Haselton D.J., Klekamp J.G., Christman B.W., Barr F.E. Use of high-dose corticosteroids and high-frequency oscillatory ventilation for treatment of a child with diffuse alveolar hemorrhage after bone marrow transplantation: case report and review of the literature. Crit Care Med 2000, 28:245-248.
91. Doerschuk C.M. Mechanisms of leukocyte sequestration in inflamed lungs. Microcirculation 2001, 8:71-88.
92. Raptis A., Mavroudis D., Suffredini A., Molldrem J., Rhee F.V., Childs R., et al. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. Bone Marrow Transplant 1999, 24:879-883.
93. Srivastava A., Gottlieb D., Bradstock K.F. Diffuse alveolar haemorrhage associated with microangiopathy after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995, 15:863-867.
94. Blatt J., Gold S.H., Wiley J.M., Monahan P.E., Cooper H.C., Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001, 28:405-407.
95. Brenner B., Hoffman R., Balashov D., Shutluko E., Culic S.D., Nizamoutdinova E. Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb Hemost 2005, 11:401-410.
96. Pihusch M., Bacigalupo A., Szer J., von Depka Prondzinski M., Gaspar-Blaudschun B., Hyveled L., et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005, 3:1935-1944.
97. Solomonov A., Fruchter O., Zuckerman T., Brenner B., Yigla M. Pulmonary hemorrhage: a novel mode of therapy. Respir Med 2009, 103:1196-1200.
98. O E, Lee B.H., Ahn H.Y., Shin J.C., Kim H.K., Kim M., et al. Efficient nonadhesive ex vivo expansion of early endothelial progenitor cells derived from CD34+ human cord blood fraction for effective therapeutic vascularization. FASEB J 2011, 25:159-169.
99. Dar A., Domev H., Ben-Yosef O., Tzukerman M., Zeevi-Levin N., Novak A., et al. Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb. Circulation 2012, 125:87-99.
100. Boor P., van Roeyen C.R., Kunter U., Villa L., Bucher E., Hohenstein B., et al. PDGF-C mediates glomerular capillary repair. Am J Pathol 2011, 177:58-69.